★ Growth Hormone

Tesamorelin

Growth Hormone · 5mg × 10 vials

GHRH analog. Clinically studied for visceral adipose reduction (Egrifta).

✓ 98%+ Purity ✓ Lab Tested ✓ COA on Request ✓ Discreet Shipping ✓ Direct Support
📋 Certificate of Analysis Request the third-party COA via Telegram ↗
Pricing
$190from · 10-vial kit
Shipping: $40 US · $60 international (10-vial kits only) · single vials $20, US only · free over $1,000
5mg × 10 vials$190
10mg × 10 vials$325
Order / Consult on Telegram →
Research use only · Not for human consumption
Free research consultation →
Join the research community →
0 min
Half-life
growth-hormone
Class
Overview

What Is Tesamorelin?

Tesamorelin is a stabilised synthetic analogue of full-length growth-hormone-releasing hormone (GHRH 1-44). It binds the GHRH receptor on the anterior pituitary and triggers pulsatile release of endogenous growth hormone, which in turn raises circulating IGF-1. The key structural feature is an N-terminal trans-3-hexenoyl modification that protects the molecule from dipeptidyl peptidase IV, giving it a plasma half-life of about 26 minutes against a couple of minutes for native GHRH.

Because it acts upstream of the pituitary rather than replacing GH directly, tesamorelin preserves the IGF-1 negative-feedback loop, and the trial data show a milder adverse-event profile than exogenous somatropin. Its most distinctive finding is selective reduction of visceral adipose tissue: in the pivotal Phase 3 trials that led to FDA approval as Egrifta in 2010 for HIV-associated lipodystrophy, mean visceral fat reductions were 15 to 18% over 26 weeks with relative sparing of subcutaneous fat and lean mass. Tesamorelin remains the only GHRH analogue with a current FDA approval.

Published Safety Data

What the published studies measured.

What the studies show
Measured in clinical trials
  • Injection site erythema: 8.5% vs 2.7% placebo (Falutz/Stanley pooled Phase 3) - mild, resolves with site rotation
  • Injection site pruritus (itching): 7.6% vs 0.8% placebo - mild
  • Peripheral edema (fluid retention in hands/ankles): 6.1% vs 2.3% placebo - mild to moderate, typically resolves weeks 2-4 as body adjusts to elevated IGF-1
  • Arthralgia (joint pain): 5-13% across trials - usually mild, related to fluid shift, resolves with continued use or dose reduction
  • Hypoesthesia / paresthesia (numbness, tingling, carpal-tunnel-like): 4-7% - IGF-1 driven, dose-dependent, resolves on dose reduction
  • Mean IGF-1 increase: ~80% from baseline at 26 weeks; ~47% of treated patients exceeded age-adjusted upper limit at some point during treatment
  • Glucose tolerance: HbA1c bumped a mean +0.1% in trials; 5% of tesa group hit HbA1c ≥6.5% vs 1% placebo. Fasting glucose unchanged at 26 weeks in non-diabetic cohort. In the dedicated T2D trial, no significant glucose worsening over 12 weeks at 2 mg/day.
  • Anti-tesamorelin IgG antibodies: ~50% develop them, did not affect efficacy or safety in the majority
The Research

Peer-reviewed studies and clinical guidelines - tap any to read the source.

PubMed / NEJMFalutz et al, NEJM 2007 - Metabolic Effects of a Growth Hormone-Releasing Factor in HIV (NCT00123345)

](https://www.nejm.org/doi/full/10.1056/NEJMoa072375) - landmark pivotal trial, 412 patients, 15-18% VAT reduction at 26 weeks on 2 mg/day SC

Read study ↗PubMedFalutz et al, 2010 - randomized trial with safety extension (PMID 20101189)

](https://pubmed.ncbi.nlm.nih.gov/20101189/) - 52-week safety/efficacy data

Read study ↗PubMedFalutz et al, 2010 - pooled Phase 3 analysis (PMID 20554713)

](https://pubmed.ncbi.nlm.nih.gov/20554713/) - combined two Phase 3 trials, AE rates and IGF-1 data

Read study ↗PubMedStanley et al, Lancet HIV 2019 - Tesamorelin on NAFLD in HIV

32% liver fat reduction at 12 months, fibrosis prevention

Read study ↗PubMedStanley et al, JCI Insight 2020 - hepatic transcriptomic effects

mechanism of liver fat reduction

Read study ↗PubMedReduction in visceral adiposity associated with improved metabolic profile (PMID 22495074)

](https://pmc.ncbi.nlm.nih.gov/articles/PMC3348954/) - metabolic profile improvements paralleling VAT loss

Read study ↗
+ 9 more studies & references

Reconstitution & Storage

Storage: refrigerated, 28 days after reconstitution. Unreconstituted vials refrigerated (lyophilized form is more forgiving but keep cold).

All products sold for research purposes only. Not for human or animal consumption. Must be 21 or older to purchase. By placing an order you confirm compliance with all applicable local laws and regulations.